Clinical study of the Avastin intravitreal injection to thick macula after surgery of epiretinal membrane

Clinical study of the Avastin intravitreal injection to thick macula after surgery of epiretinal membrane - The Avastin intravitreal injection to thick macula after surgery of epiretinal membrane

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015286

Enrollment

Registered

2014-09-29

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epiretinal Membrane

Interventions

Intravitreal injection of bevasizmab(Avastin) for residual macular edema after epiretinal membrane removal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients underwent vitrectomy for epiretinal membrane in more than 3 months ago. The patients with macular edema, and the central retinal thickness is more than 300 micro meters.

Exclusion criteria

Exclusion criteria: The patients with other associated ocular and macular conditions that compromised visual acuity Inability to obtain photographs of ocular fundus.

Design outcomes

Primary

Measure	Time frame
The rate of disappearance of the exudative retinal detachment and/or retinal edema after the treatment.	—

Countries

Japan

Contacts

Public ContactYusuke Shiode

Okayama University Hospital Department of Ophthalmology

shiode2001@yahoo.co.jp086-235-7297

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026